CONTINENTAL STRATEGY, LLC

Lobbying for IMMIX BIOPHARMA, INC. · A clinical-stage biopharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $105,000.00 income · posted Jul 19, 2026

Lobbying activity 1

Medical/Disease Research/Clinical Labs

FDA approval standards

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem